Key result
Empirical superior vena cava isolation reduced atrial tachyarrhythmia recurrence in observational studies but not in RCTs, with less benefit in non-paroxysmal AF (p=0.044) and hypertension (p=0.012).
Why the study?
Atrial tachyarrhythmia recurrence remains high after pulmonary vein isolation, with the superior vena cava being a common source of non-pulmonary vein foci.
Does empirical superior vena cava isolation reduce atrial tachyarrhythmia recurrence in patients undergoing atrial fibrillation ablation?
Meta-Analysis
Does empirical superior vena cava isolation reduce atrial tachyarrhythmia recurrence in patients undergoing atrial fibrillation ablation?
Empirical SVC isolation may reduce atrial tachyarrhythmia recurrence in initial AF ablations, though this benefit was observed in observational studies rather than RCTs.
Empirical SVC isolation should not yet alter ablation practice; leaves open efficacy in paroxysmal AF without hypertension.
Background: Atrial tachyarrhythmia (ATa) recurrence remains high after pulmonary vein isolation (PVI), with the superior vena cava (SVC) being a common source of non-pulmonary vein foci. Objective: -regression analysis regarding the empirical SVC isolation (eSVCi) versus no eSVCi in atrial fibrillation (AF) ablation. Methods: A systematic review was conducted on studies comparing eSVCi to no eSVCi (PVI-only or adjunctive SVC isolation). The primary outcome was ATa recurrence, defined as AF/atrial flutter/atrial tachycardia lasting over 30 s after a blanking period. Secondary outcomes included procedural duration, fluoroscopic duration, and complications. Results: = 40.7 %). Subgroup analysis revealed eSVCi reduced ATa recurrence in observational studies but not in RCTs, and in initial ablations but not repeat procedures. eSVCi was beneficial in both PVI-only and adjunctive SVC isolation subgroups. Meta-regression showed the benefit of eSVCi was less in patients with non-paroxysmal AF (p = 0.044) and hypertension (p = 0.012). Procedural time, fluoroscopic time, and complications were similar between the two groups. Conclusion: eSVCi potentially reduce ATa recurrence compared to no eSVCi, without increasing complications or prolonging procedural times.
No takes yet. Share an insight, caveat, or question.
Pranata et al. (2025) conducted a meta-analysis in atrial fibrillation. empirical superior vena cava isolation (eSVCi) vs. no eSVCi was evaluated on Atrial tachyarrhythmia (ATa) recurrence, defined as AF/atrial flutter/atrial tachycardia lasting over 30 s after a blanking period. Empirical superior vena cava isolation reduced atrial tachyarrhythmia recurrence in observational studies but not in RCTs, with less benefit in non-paroxysmal AF (p=0.044) and hypertension (p=0.012).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: